TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21638159

Group type: EXPERIMENTAL
Intervention: HIV risk reduction counselling intervention (one session, 180 min)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 150
Study: 19661958

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + 500 ml water prior to each daily meal (water group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hypocaloric diet alone (nonwater group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 500 ml water preload (WP)
Number of subjects: 48
Study: 18598003

Group type: EXPERIMENTAL
Intervention: 30 mg/kg of bimosiamose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15860254

Group type: EXPERIMENTAL
Intervention: Spironolactone (low doses) added to standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone (selective MR antagonist)
Number of subjects: 0
Study: 12578923

Group type: EXPERIMENTAL
Intervention: Right mesial temporal sclerosis (MTS)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Left MTS, right or left temporal lobe lesions other than MTS, or extratemporal seizure foci
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: All subjects with right TLE
Number of subjects: 146
Study: 10593458

Group type: EXPERIMENTAL
Intervention: Heated gas insufflation (37 degrees C)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unheated gas insufflation (24 degrees C)
Number of subjects: 37
Study: 8694020

Group type: COMPARATOR
Intervention: 0 g lactose (lactose-free milk)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.5 g lactose
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1.5 g lactose
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 7 g lactose
Number of subjects: 39

Group type: COMPARATOR
Intervention: lactose-free milk
Number of subjects: 39
Study: 1687254

Group type: COMPARATOR
Intervention: Incision and banding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Emergency haemorrhoidectomy
Number of subjects: 30
Study: 6577031

Group type: EXPERIMENTAL
Intervention: Plaque control instructions using the modified Bass brushing technique with no disclosant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Plaque control instructions supplemented with instructions in the use of a Plaklite
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no structured plaque control instructions)
Number of subjects: 24
Study: 29499976

Group type: EXPERIMENTAL
Intervention: 350 μg/week sublingual vitamin B12 (Ld)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2000 μg/week sublingual vitamin B12 (Hd)
Number of subjects: 40
Study: 28093634

Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of bone turnover markers (BTMs) PINP and CTX at baseline and 3 months after starting therapy
Number of subjects: 0
Study: 26094080

Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pemetrexed and cisplatin (control group)
Number of subjects: 96
Study: 24144572

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation (auricular acupressure combined with transcutaneous electric acupoint stimulation at true acupoint)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham group (acupoint stimulation at sham acupoint without embedding seeds)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no acupoint stimulation)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (AS, sham, control)
Number of subjects: 90
Study: 22160143

Group type: EXPERIMENTAL
Intervention: Merocel standard 8‐cm nasal dressing without airway
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Doyle Combo splint (DCS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Merocel in a glove finger
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Vaseline gauze
Number of subjects: 119
Study: 18723124

Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation
Number of subjects: 0
Study: 17322490

Group type: EXPERIMENTAL
Intervention: 1000 mg calcium supplementation
Number of subjects: 33

Group type: COMPARATOR
Intervention: No calcium supplementation
Number of subjects: 33
Study: 15216448

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30
Study: 11576153

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9668930

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (abstinent, moderate, heavy drinking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster analysis methods (complete and average linkage with cosine similarity)
Number of subjects: 0
Study: 8091142

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid (subgroup of N = 123)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo (subgroup of N = 123)
Number of subjects: 570
Study: 3384970

Group type: EXPERIMENTAL
Intervention: Anxiety Induction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Depression Induction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hostility Induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neutral Induction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mood Reversal
Number of subjects: 40
Study: 31800490

Group type: EXPERIMENTAL
Intervention: Primary open strategy for port implantation
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Closed strategy for port implantation
Number of subjects: 1159
Study: 30465817

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide metabolite (EZEG)
Number of subjects: 28
Study: 28444660

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exergaming
Number of subjects: 8
Study: 25410965

Group type: EXPERIMENTAL
Intervention: PMTO (Parent Management Training-the Oregon model)
Number of subjects: 102

Group type: COMPARATOR
Intervention: SAU (services usually offered in the communities)
Number of subjects: 102
Study: 23216762

Group type: EXPERIMENTAL
Intervention: Artificial gravity (AG) exercise countermeasure (CM) group, exposed to AG for 30 min, twice daily, with ergometric exercise at 40 W intensity.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no AG exercise training).
Number of subjects: 12
Study: 21983379

Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Light smokers
Number of subjects: 32
Study: 19238653

Group type: EXPERIMENTAL
Intervention: RWJ-800088 (doses > or = 0.75 microg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RWJ-800088 (doses 2.5 and 3.0 microg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RWJ-800088 (two highest doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RWJ-800088
Number of subjects: 40
Study: 17044763

Group type: EXPERIMENTAL
Intervention: TTM-based expert system intervention (three individualized expert system reports and a stage-matched manual over 6 months)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: TTM-based expert system intervention
Number of subjects: 1227
Study: 14554075

Group type: EXPERIMENTAL
Intervention: Brushing with Sensodyne
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brushing with Emoform
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brushing with Sorriso
Number of subjects: 50

Group type: COMPARATOR
Intervention: No brushing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 50
Study: 11003347

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: i.v. ganciclovir (5 mg/kg q 12 hr for 7 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 72

Group type: COMPARATOR
Intervention: No antiviral prophylaxis (for patients without CMV antigenemia)
Number of subjects: 72
Study: 8794491

Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1736831

Group type: EXPERIMENTAL
Intervention: UFT-M (UFT, Mitomycin C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: UFT-D (UFT, Doxorubicin)
Number of subjects: 62
Study: 6146425

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol after Nadolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nadolol after Propranolol
Number of subjects: 14
Study: 3536889

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 74

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 74
Study: 30239667

Group type: EXPERIMENTAL
Intervention: Improved urban environment (IUE) with coaching (C+)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Improved urban environment (IUE) without coaching (C-)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (WIUE) with coaching (C+)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (WIUE) without coaching (C-)
Number of subjects: 52
Study: 26727410

Group type: EXPERIMENTAL
Intervention: CT-Belief techniques
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CT techniques (directive CT techniques - CT-Concrete)
Number of subjects: 59
Study: 24100751

Group type: EXPERIMENTAL
Intervention: Upper endoscopy first
Number of subjects: 163

Group type: COMPARATOR
Intervention: Colonoscopy first
Number of subjects: 163
Study: 23988908

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1,450 ppm fluoride
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Dentifrice containing insoluble calcium compound and 1,450 ppm fluoride
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control dentifrice containing 1,450 ppm fluoride
Number of subjects: 6000
Study: 20573923

Group type: EXPERIMENTAL
Intervention: Fractional doses of inactivated poliovirus vaccine (0.1 ml, intradermally)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Full doses of inactivated poliovirus vaccine (intramuscularly)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fractional doses of inactivated poliovirus vaccine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Full doses of inactivated poliovirus vaccine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 18769864

Group type: EXPERIMENTAL
Intervention: Oral levetiracetam (LEV) 500 mg twice daily
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 16835214

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 150 mg daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 14693303

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg, titrated to 160 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Number of subjects: 421

Group type: COMPARATOR
Intervention: Amlodipine 5 mg, titrated to 10 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Number of subjects: 421
Study: 10867446

Group type: EXPERIMENTAL
Intervention: Metrifonate 60/80 mg
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Metrifonate 30-60 mg
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2016
Study: 8657520

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study: 1889243

Group type: EXPERIMENTAL
Intervention: High intensity, symptom-limited, endurance exercise training
Number of subjects: 52
Study: 6357936

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, acute administration)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol (chronic administration, dosage reducing heart rate by 25%)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol (acute and chronic administration)
Number of subjects: 13
Study: 30289371

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study: 30232865

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation exercise
Number of subjects: 196

Group type: COMPARATOR
Intervention: Rehabilitation exercise (control group)
Number of subjects: 196
Study: 26626336

Group type: EXPERIMENTAL
Intervention: Training group (n=10) performing barbell back squats and deadlifts twice per week for four weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 22
Study: 24462241

Group type: EXPERIMENTAL
Intervention: Motivationally-enhanced viral hepatitis education and counseling intervention
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard counseling (Control)
Number of subjects: 440
Study: 22595353

Group type: EXPERIMENTAL
Intervention: Intraventricular urokinase (Uk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19903658

Group type: EXPERIMENTAL
Intervention: AA plus G (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: G only (control dialysate)
Number of subjects: 12
Study: 18572233

Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention with bupropion and nicotine patch, including a pedometer, counseling to increase steps by 10% biweekly towards a 10,000 steps/day goal, and personalized reports for 40 weeks.
Number of subjects: 407

Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention with bupropion and nicotine patch.
Number of subjects: 407
Study: 16032913

Group type: EXPERIMENTAL
Intervention: Computer-assisted video instruction (customized set of exercises downloaded from a computerized database)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine rehabilitation practice (traditional group received routine inpatient rehabilitation exercise education from physical therapists)
Number of subjects: 40
Study: 11581563

Group type: EXPERIMENTAL
Intervention: High-resistance (HR) training, 3 times per week at 80% maximum strength (1RM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Variable-resistance (VR) training, 3 times per week at 80%, 65%, and 50% 1RM
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 9532686

Group type: EXPERIMENTAL
Intervention: Hep-A-in-Vac vaccine
Number of subjects: 14000
Study: 7976448

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medication-free clinical treatment
Number of subjects: 66
Study: 2563389

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 53
Study: 799992

Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 312

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 312
Study: 31022252

Group type: EXPERIMENTAL
Intervention: Preventive treatments for RA (e.g., non-biologic drugs like hydroxychloroquine, atorvastatin, biologics)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Oral treatment vs. infusion
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Increasing reduction in risk of RA
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Health care professional preference
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Avoiding irreversible serious side effects
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Avoiding reversible serious side effects
Number of subjects: 288
Study: 30573748

Group type: EXPERIMENTAL
Intervention: Licensed trivalent influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel virus-like particle based vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 26986471

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (ISTp) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Number of subjects: 36
Study: 25210017

Group type: EXPERIMENTAL
Intervention: Continuous oral lenalidomide (20 mg/day)
Number of subjects: 45
Study: 22691399

Group type: EXPERIMENTAL
Intervention: Experimental group (teacher-focused intervention)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 1158
Study: 19050386

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg intravenous)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17515448

Group type: EXPERIMENTAL
Intervention: Atomoxetine 18 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15223527

Group type: EXPERIMENTAL
Intervention: Multi-session groupwork for HIV prevention
Number of subjects: 50
Study: 11600352

Group type: EXPERIMENTAL
Intervention: Reference capsule formulation of amoxicillin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Test capsule formulation of amoxicillin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reference and test suspensions of amoxicillin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Various amoxicillin formulations (250 to 1,000 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: LSS-derived AUC(0-infinity) and C(max)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two-point LSS models for T>MICs of 0.25 or 2.0 microg/ml
Number of subjects: 48
Study: 9425650

Group type: EXPERIMENTAL
Intervention: Symptom‐/NCS‐ hands
Number of subjects: 27

Group type: COMPARATOR
Intervention: NCS‐ hands
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NCS+ hands
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ratio of the change in pinch rate with respect to required pinch force
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pinch rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gap detection threshold and the ratio of the change in pinch rate with respect to required pinch force
Number of subjects: 27
Study: 7584262

Group type: EXPERIMENTAL
Intervention: Perceptual cues (fragment cues)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conceptual cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit retrieval
Number of subjects: 0
Study: 3120487

Group type: EXPERIMENTAL
Intervention: 10 mg selegiline (1‐deprenyl)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg Madopar + 10 mg selegiline (1‐deprenyl)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 200 mg Madopar + placebo
Number of subjects: 15
Study: 31351189

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg/300 mg
Number of subjects: 1902
Study: 30563816

Group type: EXPERIMENTAL
Intervention: Education session by pharmacists (60 minutes)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study: 27310616

Group type: EXPERIMENTAL
Intervention: Training of family physicians (FPs) to diagnose MCI and dementia (intervention component 1)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Case finding of MCI and dementia and care by a trained nurse and the FP (intervention component 2)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Mental health assessment among consenting participants in trial stage 2
Number of subjects: 647
Study: 24758510

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optical coherence tomography guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 23575810

Group type: EXPERIMENTAL
Intervention: Vigabatrin (3.0 g/d)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 19912207

Group type: EXPERIMENTAL
Intervention: Tolterodine combined with behavioral therapies including individualized fluid management instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General fluid management instructions
Number of subjects: 0
Study: 18240033

Group type: EXPERIMENTAL
Intervention: Lifetime history of suicide attempt
Number of subjects: 1245
Study: 16316699

Group type: EXPERIMENTAL
Intervention: Coronary risk factors and inflammation assessment in CAD patients with ICD implants
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Total cholesterol and LDL cholesterol levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: hs-CRP levels
Number of subjects: 110
Study: 12746013

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normally menstruating
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 10982759

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic‐interpersonal (PI) psychotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 95
Study: 8993956

Group type: EXPERIMENTAL
Intervention: Homoeopathic therapy (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo therapy (n = 30)
Number of subjects: 60